CNGA3 and achromatopsia: Moreover, gene therapy of achromatopsia caused by mutations in the CNGA3 gene has already reached the clinical phase, and a trial with subretinal AAV8.CNGA3 gene therapy in nine patients with CNGA3-linked achromatopsia demonstrated a good safety profile over 3 years (Reichel et al. 2022).